A vaccine directed against tumour blood vessels suppress tumour growth and metastasis

Google+ Pinterest LinkedIn Tumblr +

vaccine ampule oncology news australia_800x500In a new study published in the scientific journal Oncotarget researchers from Uppsala University show that a therapeutic vaccine directed against tumour vessels can reduce tumour burden and suppress formation of spontaneous lung metastases in a mouse model for metastatic breast cancer.

The target molecule of the immunisation strategy is the extra domain-A (ED-A) of fibronectin, a protein domain which is highly selective for the tumour vasculature in the adult.

“The vaccination approach we have employed is not prophylactic but therapeutic, meaning that immunity was induced after the onset of tumourigenesis – a scenario that resembles the clinical conditions much more closely than prophylactic immunisation studies, says Anna-Karin Olsson, researcher at the Department of Medical Biochemistry and Microbiology at Uppsala University”, who has led the study.

The therapeutic effect was significant, despite the aggressive nature of the tumour model. Moreover, the vaccine induced an 80 percent reduction metastasis, which is an important finding considering that a majority of all deaths by cancer are caused by cancer that has spread in the body.

A major advantage of the approach is that the target molecule ED-A is present in the majority of solid tumours. Vaccination against ED-A could therefore provide a treatment strategy with broad applications in cancer therapy. Furthermore, the researchers show that their strategy for immunisation against a self-molecule is highly efficient and can be achieved with an adjuvant (immunostimulatory compound included in vaccines) that is acceptable for use in the clinic. The lack of potent, but at the same time non-toxic and biodegradable adjuvants has been a major limitation in the development of therapeutic vaccines.

Another important aspect is that therapeutic vaccination (endogenous production of the target antibodies) can provide a cost-efficient alternative to administration of large amounts of monoclonal antibodies, currently in clinical use for cancer and other diseases. The high costs associated with monoclonal antibody-based therapies puts a significant strain on the health-care economy, which may limit accessibility for patients.

“In conclusion, we believe therapeutic vaccination could provide a new, potent and cost-efficient treatment strategy for solid tumours and metastasising cancer”, says Anna-Karin Olsson.

Source: Uppsala University

Share.

About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Comments are closed.